Sign in

You're signed outSign in or to get full access.

Edward

Research Analyst at Leerink

Edward Tan is an Equity Research Analyst at Leerink Partners, specializing in biopharma and biotech sectors. He covers specific companies including Vaxcyte, with active participation in earnings calls posing insightful questions. Tan's background includes expertise in research and financial analysis within the life sciences field; specific performance metrics, detailed career timeline, previous firms, and professional credentials such as FINRA registrations are not publicly detailed in available sources.

Edward's questions to Vaxcyte (PCVX) leadership

Question · Q4 2025

Edward asked about the current trends in PCV uptake for adults aged 50 years and above.

Answer

Mike Miletich, Chief Commercial Officer of Vaxcyte, reported positive market signals, including progressing uptake in the 50-64 age group by Pfizer and Merck, and Capvaxive's strong market share gains. Grant Pickering, CEO, added that international adoption in developed countries is also increasing, contributing to a substantial overall opportunity for adult PCVs.

Ask follow-up questions

Fintool

Fintool can predict Vaxcyte logo PCVX's earnings beat/miss a week before the call

Question · Q4 2025

Edward asked about the current trend of PCV uptake for adults aged 50 and above.

Answer

Mike Miletich, Chief Commercial Officer of Vaxcyte, reported positive signals, including progressing uptake in the 50-64 age group (though potentially impacted by lower Q4 flu vaccination rates). He highlighted Capvaxive's market share gains, Merck's strong US earnings, and increasing international adult vaccination adoption in Europe, Japan, and Canada. Grant Pickering, CEO, added that the US is an outlier with its 50+ recommendation, while international adoption is growing, typically for older age groups.

Ask follow-up questions

Fintool

Fintool can write a report on Vaxcyte logo PCVX's next earnings in your company's style and formatting